首页> 美国卫生研究院文献>Oncotarget >KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma
【2h】

KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma

机译:内镜超声引导下细针穿刺抽吸冲洗液的KRAS突变分析可改善胰腺导管腺癌的细胞学诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

EUS-FNA becomes one of the most important diagnostic modalities for PDACs. However, acquired tissue specimens were sometimes insufficient to make a definite cytological diagnosis. On the other hand, KRAS mutation is the most frequently acquired genetic alteration found more than 90% of PDACs. To investigate the way to improve diagnostic accuracy for PDACs using both cytological examination and KRAS mutation analysis would be a great help. Therefore, the aims of this study were to evaluate usefulness of conventional cytological examination combined with KRAS mutation analysis with modified PCR technology to improve the sensitivity and the accuracy. We enrolled 43 patients with solid pancreatic masses and 86 EUS-FNA specimens were obtained. During the EUS-FNA, the needle catheter was flushed with 2 cc of saline and the washed fluid was collected for KRAS mutation analysis for the first 2 passes; PNAClamp™ KRAS Mutation Detection Kit. There were 46 specimens from the 23 PDACs and 40 specimens from the 20 other pancreatic diseases. The sensitivity, specificity and accuracy were as follows; conventional cytopathologic examination: 63%, 100% and 80%; combination of cytopathologic examination and K-ras mutation analysis: 87%, 100% and 93%. Furthermore, KRAS mutation was detected 11 out of 17 PDAC samples whose cytopathology results were inconclusive. KRAS mutation analysis with PNAClamp™ technique using washing fluid from EUS-FNA along with cytological examination may not only improve the diagnostic accuracy of PDACs, but also establish the platform using genetic analysis which would be helpful as diagnostic modality for PDACs.
机译:EUS-FNA成为PDAC最重要的诊断方式之一。但是,获得的组织标本有时不足以进行明确的细胞学诊断。另一方面,在超过90%的PDAC中,KRAS突变是最常见的遗传变异。利用细胞学检查和KRAS突变分析研究提高PDAC诊断准确性的方法将有很大帮助。因此,本研究的目的是评估常规细胞学检查与结合改进的PCR技术的KRAS突变分析相结合的有效性,以提高灵敏度和准确性。我们招募了43例实性胰腺肿块患者,并获得了86例EUS-FNA标本。在EUS-FNA期间,用2 cc盐水冲洗针导管,并在前两遍收集洗过的液体用于KRAS突变分析。 PNAClamp™KRAS突变检测试剂盒。来自23个PDAC的46个标本和来自其他20种胰腺疾病的40个标本。敏感性,特异性和准确性如下:常规细胞病理检查:63%,100%和80%;细胞病理学检查和K-ras突变分析相结合:分别为87%,100%和93%。此外,在17份细胞病理学结果不确定的PDAC样品中,有11份检测到KRAS突变。使用EUS-FNA冲洗液和细胞学检查结合PNAClamp™技术进行的KRAS突变分析不仅可以提高PDAC的诊断准确性,而且可以利用遗传分析建立平台,这将有助于PDAC的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号